Video

The Antiangiogenic Quagmire

Publish date: October 31, 2011

 

Is there a future for antiangiogenic therapy with hormone therapy in hormone receptor-positive breast cancer? Dr. Hope Rugo discusses a failed sorafenib trial in the last of 3 video commentaries from the European Multidisciplinary Cancer Congress in Stockholm.

Recommended Reading

MRI Breast Screening Effective for Underserved Women
MDedge Hematology and Oncology
Score Predicts Late Recurrence in ER-Positive Breast Cancer
MDedge Hematology and Oncology
Chemo Timing Does Not Affect Breast Cancer Recurrence
MDedge Hematology and Oncology
Trastuzumab-Based T-DM1 Delays Breast Cancer Progression
MDedge Hematology and Oncology
Everolimus Posts Big Win in ER-Positive Breast Cancer
MDedge Hematology and Oncology
Prone Position During Breast Irradiation Lessens Lung Cancer Risk
MDedge Hematology and Oncology
California Insurer Drops Bevacizumab Breast Cancer Coverage
MDedge Hematology and Oncology
Multimodal DCIS Therapy, Tamoxifen Cuts Breast Cancer Deaths
MDedge Hematology and Oncology
Mammography's Role in Saving Lives Deemed Exaggerated
MDedge Hematology and Oncology
Meeting Highlights From the 2011 Breast Cancer Symposium
MDedge Hematology and Oncology